| Literature DB >> 25562047 |
Nan-He Yoon1, Seunghyun Yoo2, Hyekyeong Kim3.
Abstract
OBJECTIVES: The aim of this study was to examine the composition of metabolic syndrome (MetS) components among middle-aged and older Koreans.Entities:
Keywords: CVD risk factors; clustering; lifestyle intervention; metabolic syndrome
Year: 2014 PMID: 25562047 PMCID: PMC4281635 DOI: 10.1016/j.phrp.2014.10.005
Source DB: PubMed Journal: Osong Public Health Res Perspect ISSN: 2210-9099
Baseline characteristics and risk factors for metabolic syndrome.
| Men ( | Women ( | All ( | |||
|---|---|---|---|---|---|
| Sociodemographic characteristics | |||||
| Age (y) | Mean (SD) | 56.9 (9.1) | 58.1 (7.4) | 57.7 (8.0) | 0.2566 |
| Education (6 missed) | Middle school | 18 (19.4) | 78 (47.6) | 96 (37.4) | <0.0001 |
| High school | 41 (44.1) | 52 (31.7) | 93 (36.2) | ||
| College | 34 (36.6) | 34 (20.7) | 68 (26.5) | ||
| Marital status (5 missed) | Live with spouse | 86 (92.5) | 130 (78.8) | 216 (83.7) | 0.0043 |
| Live without spouse | 7 (7.5) | 35 (21.2) | 42 (16.3) | ||
| Working (5 missed) | Employed | 60 (64.5) | 58 (35.2) | 118 (45.7) | <0.0001 |
| Housewives | 0 (0.0) | 94 (57.0) | 94 (36.4) | ||
| Others | 33 (35.5) | 13 (7.9) | 46 (17.8) | ||
| Monthly income (13 missed) | >US$1000 | 10 (11.4) | 37 (22.8) | 47 (18.8) | 0.0733 |
| US$1000–3000 | 40 (45.5) | 69 (42.6) | 109 (43.6) | ||
| ≥US$3000 | 38 (43.2) | 56 (34.6) | 94 (37.6) | ||
| Metabolic syndrome (MetS) characteristics | |||||
| No. of MetS components, mean (SD) | 3.3 (0.5) | 3.2 (0.4) | 3.2 (0.5) | 0.0949 | |
| 3 components | 68 (73.1) | 139 (81.8) | 207 (78.7) | 0.1725 | |
| 4 components | 22 (23.7) | 29 (17.1) | 51 (19.4) | ||
| 5 components | 3 (3.2) | 2 (1.2) | 5 (1.9) | ||
| Elevated blood pressure (EBP) | 79 (84.9) | 115 (67.6) | 194 (73.8) | 0.0023 | |
| Abdominal obesity (AO) | 72 (77.4) | 147 (86.5) | 219 (83.3) | 0.0601 | |
| Impaired fasting glucose (IFG) | 73 (78.5) | 98 (57.6) | 171 (65.0) | 0.0007 | |
| Elevated triglycerides (ETG) | 72 (77.4) | 108 (63.5) | 180 (68.4) | 0.0205 | |
| Low HDL cholesterol (HDL) | 11 (11.8) | 75 (44.1) | 86 (32.7) | <0.0001 | |
ap value was based on a t test for continuous variables and the Chi-square tests and Fisher's exact tests for categorical variables.
HDL cholesterol = high-density lipoprotein cholesterol; SD = standard deviation.
Prevalence rates and cluster effects of MetS component combinations at baseline.
| Prevalence of MetS components | Men ( | Women ( | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| EBP | AO | IFG | ETG | HDL | ||||||
| (%) | (%) | |||||||||
| + | + | + | + | + | 3 (3.2) | 4.7 | 0.68 | 2 (1.2) | 9.5 | 0.12 |
| + | + | + | + | − | 20 (21.5)*** | 35.2 | 0.61 | 7 (4.1) | 12.0 | 0.34 |
| + | + | + | − | + | 0 (0.0) | 1.4 | 0.00 | 4 (2.4) | 5.4 | 0.43 |
| + | + | − | + | + | 0 (0.0) | 1.3 | 0.00 | 10 (5.9) | 6.9 | 0.85 |
| + | − | + | + | + | 2 (2.2) | 1.4 | 1.56 | 0 (0.0) | 1.5 | 0.00 |
| − | + | + | + | + | 0 (0.0) | 0.8 | 0.00 | 8 (4.7) | 4.5 | 1.04 |
| + | + | + | − | − | 20 (21.5) | 10.3 | 2.09 | 42 (24.7) | 6.9 | 3.59 |
| + | + | − | + | − | 15 (16.1) | 9.7 | 1.67 | 19 (11.2) | 8.8 | 1.27 |
| + | + | − | − | + | 0 (0.0) | 0.4 | 0.00 | 13 (7.6) | 4.0 | 1.92 |
| + | − | + | + | − | 15 (16.1)** | 10.3 | 1.57 | 8 (4.7) | 1.9 | 2.51 |
| + | − | + | − | + | 0 (0.0) | 0.4 | 0.00 | 2 (1.2) | 0.9 | 1.39 |
| + | − | − | + | + | 4 (4.3) | 0.4 | 11.39 | 8 (4.7) | 1.1 | 4.33 |
| − | + | + | + | − | 12 (12.9) | 6.2 | 2.07 | 19 (11.2) | 5.7 | 1.95 |
| − | + | + | − | + | 1 (1.1) | 0.2 | 4.40 | 1 (0.6) | 2.6 | 0.23 |
| − | + | − | + | + | 1 (1.1) | 0.2 | 4.69 | 22 (12.9)** | 3.3 | 3.90 |
| − | − | + | + | + | 0 (0.0) | 0.2 | 0.00 | 5 (2.9) | 0.7 | 4.16 |
**p < 0.01 and ***p < 0.001 based on Chi-square tests and Fisher's exact tests for categorical variables.
AO = abdominal obesity; E = expected prevalence rates; EBP = elevated blood pressure; ETG = elevated triglycerides; HDL = low high-density lipoprotein cholesterol; IFG = impaired fasting glucose; MetS = metabolic syndrome; O = observed prevalence rates.
Ratio of observed and expected prevalence (O/E)≥1.50.
Figure 1Improvements in the prevalence of MetS risks. The p value based on Chi-square tests for comparison of prevalence rates changes between men and women. AO = abdominal obesity; EBP = elevated blood pressure; ETG = elevated triglycerides; HDL = low high-density lipoprotein cholesterol; IFG = impaired fasting glucose.
Cluster effects of changes in MetS components' prevalence rates.
| Changes in MetS components | Men | Women | |||||
|---|---|---|---|---|---|---|---|
| (%) | (%) | (%) | (%) | ||||
| EBP | AO | 5.17 | 6.75 | 0.77 | 8.25 | 9.94 | 0.83 |
| EBP | IFG | 11.67 | 9.16 | 1.27 | 18.46 | 15.44 | 1.20 |
| EBP | ETG | 18.64 | 11.81 | 1.58 | 27.78 | 25.12 | 1.11 |
| EBP | HDL | 44.44 | 13.81 | 3.22 | 15.38 | 15.30 | 1.00 |
| AO | IFG | 7.14 | 6.70 | 1.07 | 6.02 | 5.64 | 1.07 |
| AO | ETG | 9.80 | 8.64 | 1.13 | 14.94 | 9.17 | 1.63 |
| AO | HDL | 20.00 | 10.10 | 1.98 | 11.67 | 5.59 | 2.09 |
| IFG | ETG | 13.46 | 11.72 | 1.15 | 12.24 | 14.25 | 0.86 |
| IFG | HDL | 16.67 | 13.70 | 1.22 | 4.55 | 8.68 | 0.52 |
| ETG | HDL | 40.00 | 17.68 | 2.26 | 18.18 | 14.12 | 1.29 |
AO = abdominal obesity; E = expected prevalence rates; EBP = elevated blood pressure; ETG = elevated triglycerides; HDL = low high-density lipoprotein cholesterol; IFG = impaired fasting glucose; MetS = metabolic syndrome; O = observed probabilities of changes.
Ratio of observed and expected prevalence (O/E) ≥1.50.
Prevalence rates, cluster effects and prevalence odds ratio of MetS components after the intervention.
| MetS components | Men ( | Women ( | |||||||
|---|---|---|---|---|---|---|---|---|---|
| POR | POR | ||||||||
| (%) | (%) | (%) | (%) | ||||||
| EBP | AO | 40.86 | 38.85 | 1.05 | 1.365 | 31.18 | 28.52 | 1.09 | 1.771 |
| EBP | IFG | 37.63 | 37.46 | 1.00 | 0.960 | 21.18 | 17.85 | 1.19 | 1.770 |
| EBP | ETG | 39.78 | 36.07 | 1.10 | 1.847 | 14.12 | 15.53 | 0.91 | 0.780 |
| EBP | HDL | 9.68 | 10.41 | 0.93 | 0.809 | 16.47 | 17.85 | 0.92 | 0.798 |
| AO | IFG | 35.48 | 34.96 | 1.01 | 0.935 | 34.71 | 32.77 | 1.06 | 1.504 |
| AO | ETG | 33.33 | 33.67 | 0.99 | 0.793 | 25.88 | 28.52 | 0.91 | 0.582 |
| AO | HDL | 6.45 | 9.71 | 0.66 | 0.377 | 31.18 | 32.77 | 0.95 | 0.737 |
| IFG | ETG | 39.78 | 32.47 | 1.23 | 3.119* | 17.06 | 17.85 | 0.96 | 0.873 |
| IFG | HDL | 7.53 | 9.37 | 0.80 | 0.592 | 16.47 | 20.52 | 0.80 | 0.505* |
| ETG | HDL | 12.90 | 9.02 | 1.43 | 4.249* | 24.71 | 17.85 | 1.38 | 3.274*** |
*p < 0.05, ***p < 0.001.
AO = abdominal obesity; E = expected prevalence rates; EBP = elevated blood pressure; ETG = elevated triglycerides; HDL = low high-density lipoprotein cholesterol; IFG = impaired fasting glucose; MetS = metabolic syndrome; O = observed prevalence rates; POR = prevalence odds ratio adjusted for ages.